REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

This study tests whether adding the drug acalabrutinib to a CAR-T cell therapy (liso-cel) can improve outcomes for people with aggressive B-cell lymphoma that has returned or not responded to prior treatments. About 28 adults will receive the combination. The main goal is to see …

This early-phase study tests a combination of three drugs (alisertib, bortezomib, and rituximab) in adults with mantle cell or low-grade non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and check for side effects…

This study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…

This early-stage study tests a new cell therapy called ANCHOR cells for people with B-cell lymphoma or leukemia that has returned or not responded to standard treatments. The cells are made from a healthy donor's immune cells and are modified to better recognize and attack cancer…

This early-stage trial is testing a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study aims to find the safest dose and see if the combination can shrink or stabilize the cancer…

This study tests a combination of two drugs, epcoritamab and lenalidomide, for people with a type of lymphoma that didn't respond to treatment or came back, and who have weakened immune systems. The goal is to see if the combo can shrink or eliminate the cancer. About 34 adults w…

This study tests adding an experimental drug called selinexor to the standard chemotherapy R-CHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced …

This phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…

This early-phase study tests the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in adults with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The drugs work by blocking cancer cell survival s…

This study tracks 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to watch for long-term side effects and safety issues over 15 years. No new treatment is given—just regular check-ups to see how patients are doing.…